Journal of Research in Medical Sciences

LETTER TO EDITOR
Year
: 2021  |  Volume : 26  |  Issue : 1  |  Page : 79-

Estimated CD4+ count: Appraisal on cases with COVID-19


Beuy Joob1, Viroj Wiwanitkit2,  
1 Sanitation Medical Academic Center, Bangkok, Thailand
2 Department of Community Medicine, Dr D.Y. Patil University; Department of Tropical Medicine, Hainan Medical University, Pune, Maharashtra, India

Correspondence Address:
Dr. Beuy Joob
Sanitation Medical Academic Center, Bangkok
Thailand




How to cite this article:
Joob B, Wiwanitkit V. Estimated CD4+ count: Appraisal on cases with COVID-19.J Res Med Sci 2021;26:79-79


How to cite this URL:
Joob B, Wiwanitkit V. Estimated CD4+ count: Appraisal on cases with COVID-19. J Res Med Sci [serial online] 2021 [cited 2022 Jan 19 ];26:79-79
Available from: https://www.jmsjournal.net/text.asp?2021/26/1/79/327212


Full Text



Dear Editor,

COVID-19 infection is an emerging novel coronavirus infection.[1] This new infection started in China in December 2019. Now (March 7, 2020), it already causes health problem in more than 50 countries in all continents except for Antarctica. Clinically, this new infection causes acute febrile illness and severe respiratory distress might occur.[2],[3],[4] Regarding basic laboratory investigation, decreased lymphocyte count is a hematological finding from complete blood count.[2],[3],[4] Nevertheless, there has never reported on its effect of specific lymphocyte subsets. Here, the authors reappraised on clinical data on published data to estimate the CD4 + count in COVID-19. Based on available data on 278 cases with COVID,[2],[3],[4] the authors performed a summative analysis on total lymphocyte count (TLC) and additional estimation of CD4 count based on the mathematical model technique.[5] The referred mathematical model is “CD4 + count = 0.24 × TLC − 5.97.”[5] Based on summative analysis, the mean TLC is equal to 840 cells/μL, therefore, the derived estimated CD4+ count is equal to 195.63 cells/μL). Therefore, the low CD4+ count is observed, and this reflects the nature of immunodeficiency in COVID-19 infection. Further studies on immunopathological due to the new infection are recommended.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Hsia W. Emerging new coronavirus infection in Wuhan, China: Situation in early 2020. Case Study Case Rep 2020;10:8-9.
2Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
3Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.
4Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
5Srirangaraj S, Venkatesha D. Absolute lymphocyte count as a surrogate marker for CD4 counts after six months of HAART initiation in a resource-limited setting in India. Indian J Med Res 2012;135:895-900.